Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Next Previous
Trial Profile

Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Cetuximab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 07 May 2025 Planned End Date changed from 1 Dec 2027 to 1 Jan 2026.
  • 19 Mar 2025 Planned End Date changed from 1 Jan 2025 to 1 Dec 2027.
  • 19 Mar 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top